Clinical Associate Professor Daniel TAN
MBBS (London), MRCP (UK), BSc (Hons), FAMS 
Daniel Tan Shao Weng.jpg

Cancer Clinical Trials & Investigational Medicine Units Platform

Co-Lead

Singapore Translational Cancer Consortium 

Senior Consultant (Medical Oncology)
National Cancer Centre Singapore

Senior Consultant

SingHealth Duke-NUS Lung Centre

Adjunct Associate Professor

SingHealth Duke-NUS Oncology Academic Clinical Programme

Clinical Associate Professor Daniel Tan graduated from University College London, with an Intercalated Bachelor of Science degree in Tumour Biology, 1st Class (Honours), and MBBS from St. Bartholomew’s and Royal London Hospital School of Medicine and Dentistry. He is a Senior Consultant at the Division of Medical Oncology at National Cancer Centre Singapore (NCCS), and a senior clinician-scientist at Genome Institute of Singapore. 

 

Adjunct Associate Professor Tan main area of interest is in thoracic, head and neck malignancies and drug development. He currently leads the Experimental Cancer Therapeutic Unit (ECRU) at NCCS, and has been instrumental to growing it to one of the largest phase I unit in Asia, running up approximately 30 - 40 trials at any one time. He is also the Principal Investigator of the Cancer Therapeutics Research Laboratory at NCCS focused on developing representative patient- derived preclinical models to gain insights to drug response and resistant, complementing his role as the principles investigator for multiple biomarker-driven early phase clinical trials including first-in-human studies. He is the principal investigator for the National Medical Research Council Lung Cancer Large Collaborative Grant (2019-2023), and Chairs the Asian Thoracic Oncology Research Group, the latter set up as a platform to coordinate translational research and clinical trials in the region.

Adjunct Associate Professor Tan’s research interests include rational application of “omics” technologies to unravel drug resistance in cancer therapeutics and accelerating the development of novel agents and biomarkers in the clinic. His research has been recognised through multiple local and international awards, including European Society of Medical Oncology Congress Travel Award, American Society of Clinical Oncology (ASCO) Merit Awards, ASCO Young Investigator Award as well as most recently being awarded the IASLC Daniel C. Idhe Lectureship Award in 2019, the latter in recognition of his work in the field of medical oncology and extensive contributions to the lung cancer arena. Dr Tan also holds a SingHealth GCEO Outstanding Clinician-Researcher Award and a National Medical Research Council Clinician-Scientist Award. He has published widely in journals including Nature, Nature Medicine, The New England Journal of Medicine, The Lancet, The Lancet Oncology and Journal of Clinical Oncology. Dr Tan is the past Chair of the Education Committee of the International Association for Study of Lung Cancer (IASLC) and has participated in the organising scientific committees and faculty member for multiple international conferences including WCLC, ESMO and ASCO. In ESMO 2021, he is the track chair for translational research. He has been active in developing educational resources to enhance quality of lung cancer care globally and is currently involved in The Lancet Commission on Lung Cancer. He serves as Associate Editor for the Journal of Thoracic Oncology and is the conference chair for the World Conference in Lung Cancer, the flagship and largest interdisciplinary conference of the IASLC.

Selected Publications & Research Trials

  • Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. 

  • Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Chowbay B. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. J Thorac Oncol. 2017 Mar;12(3):529-538. doi: 10.1016/j.jtho.2016.11.2225. Epub 2016 Nov 28. 

  • Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, Lim S, Kurioka A, Fergusson JR, Tang CL, Kam MH, Dennis K, Lim TK, Fui AC, Hoong CW, Chan JK, Curotto de Lafaille M, Narayanan S, Baig S, Shabeer M, Toh SE, Tan HK, Anicete R, Tan EH, Takano A, Klenerman P, Leslie A, Tan DS, Tan IB, Ginhoux F, Newell EW. Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency. Immunity. 2017 Jan 17;46(1):148-161. doi: 10.1016/j.immuni.2016.11.005. 

  • Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 Jan 23. pii: S0140-6736(17)30123-X. doi: 10.1016/S0140-6736(17)30123-X. [Epub ahead of print] 

  • Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R, Tan EH. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett. 2016 Dec 18;388:328-333. doi: 10.1016/j.canlet.2016.12.013. [Epub ahead of print] 

Research Trials

  • A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer (DT), 2015 

  • A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer 

  • An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib (DT), 2015 

  • A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy (Dlim), 2015 

  • A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations, 2016 

  • A Phase Ib/II Multi-centre, Randomized, Open-label Trial to Compare MSC2156119J combined with Gefitinib Versus Chemotherapy as Second Line Treatment in Subjects with MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First Line Gefitinib, 2013 

  • A phase I, multi-center, open label dose escalation and expansion study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFR-mut solid malignancies, 2014 

  • A Phase Ib open-label clinical trial of once daily oral treatment of afatinib plus weekly intravenous infusion of BI 836845 in patients with EGFR mutant non-small cell lung cancer with progression following prior EGFR tyrosine kinase inhibitors, 2014